Antidiuretic Hormone Receptor Antagonists
"Antidiuretic Hormone Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous compounds and drugs that inhibit or block the activity of ANTIDUIRETIC HORMONE RECEPTORS.
| Descriptor ID |
D065092
|
| MeSH Number(s) |
D27.505.519.174 D27.505.696.560.311
|
| Concept/Terms |
Antidiuretic Hormone Receptor Antagonists- Antidiuretic Hormone Receptor Antagonists
- Vasopressin Antagonists
- Antagonists, Vasopressin
- Vasopressin Receptor Antagonists
- Antagonists, Vasopressin Receptor
- Receptor Antagonists, Vasopressin
- Antidiuretic Hormone Antagonists
- Antagonists, Antidiuretic Hormone
- Hormone Antagonists, Antidiuretic
|
Below are MeSH descriptors whose meaning is more general than "Antidiuretic Hormone Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Antidiuretic Hormone Receptor Antagonists".
This graph shows the total number of publications written about "Antidiuretic Hormone Receptor Antagonists" by people in this website by year, and whether "Antidiuretic Hormone Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 0 | 1 |
| 2012 | 3 | 1 | 4 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 3 | 0 | 3 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antidiuretic Hormone Receptor Antagonists" by people in Profiles.
-
For vaptans, as for life, balance is better. Eur J Heart Fail. 2021 05; 23(5):751-753.
-
Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. Circ Heart Fail. 2016 05; 9(5).
-
In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial. JACC Heart Fail. 2016 07; 4(7):580-588.
-
Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. Am J Cardiol. 2016 Apr 01; 117(7):1144-50.
-
Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). Am J Cardiol. 2014 Dec 01; 114(11):1713-21.
-
Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur J Heart Fail. 2013 Dec; 15(12):1401-11.
-
Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. Am Heart J. 2013 Feb; 165(2):216-25.
-
Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail. 2013 Jan; 6(1):47-52.
-
Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. Am Heart J. 2012 Dec; 164(6):884-92.e2.
-
Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial. Eur J Heart Fail. 2013 Jan; 15(1):61-8.